AMERICAN VIETNAMESE BIOTECH INC

REVIEWED INTERIM SEPARATE FINANCIAL STATEMENTS

For the accounting period from 01/01/2026 to 30/06/2026

ĐẶNG NHỊ NƯƠNG

Digitally signed by ĐẶNG NHỊ NƯƠNG
DN: C=VN, S=HỒ CHÍ MINH, L=Quận 7, O=CÔNG TY CỔ PHẦN SẢN XUẤT KINH DOANH DƯỢC VÀ TRANG THIẾT BỊ Y TẾ VIỆT MỸ, OU=Giám đốc, T=Giám đốc, CN=ĐẶNG NHỊ NƯƠNG, OID.0.9.2342.19200300.100.1.1=CCCD:001156020169
Reason: I am the author of this document
Location:
Date: 2026.08.29 00:09:52+07'00'
Foxit PDF Reader Version: 12.1.3

CONTENTS

REPORT OF THE BOARD OF MANAGEMENT

For the accounting period from 01 January 2026 to 30 June 2026

The Board of Management of American Vietnamese Biotech INC (hereinafter referred to as "the Company") presents this report together with the Reviewed Interim Separate Financial Statements for the accounting period from 01 January 2026 to 30 June 2026.

1. General information

American Vietnamese Biotech INC (hereinafter referred to as "the Company") is a joint stock company incorporated and operating in Vietnam under Business Registration Certificate No. 3800237998, initially issued on 25 August 2002, and as amended for the 24th time on 17 August 2025, issued by the Department of Finance of Ho Chi Minh City.

2. Board of Directors, Board of Management and Board or Supervisors

The members of the Board of Directors, Board of Management and Board of Supervisors who managed the Company's operations during the accounting period and up to the date of this report are as follows:

Board of Directors

Name:	Position:
- Mr. Nakatani Yoshitaka	Chairman
- Mrs. Dang Thi Nuong	Member
- Mr. Le Khanh Nguyen	Member

Board of Management and Chief Accountant

Name:	Position:
- Mr. Dang Nhi Nuong	Director
- Mr. Nguyen Thu Huyen	Chief Accountant

Board of Supervisors

Name:	Position:
- Mrs. Le Thi Huong	Chair of the Board
- Mrs. Nguyen Huong Giang	Member
- Mr. Le Huu Tri	Member

3. Legal representative

The legal representative of the Company during the accounting period and up to the date of this report is Mrs. Dang Nhi Nuong - Company Director.

4. Head office

The Company's head office is located at: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City.

5. Unusual items and events occurring after the end of the accounting period

Up to the date of this report, the Board of Management of the Company considers that there have been no events which may cause the figures and information presented in the Company's reviewed Interim Separate Financial Statements to be materially misstated.

6. Audit firm

PKF-TTG Audit and Consulting Company Limited has been appointed as the auditor to perform the review of the Company's Interim Separate Financial Statements for the accounting period from 01 January 2026 to 30 June 2026.

7. Statement of the Board of Management's responsibility for the Interim Financial Statements

The Board of Management of the Company is responsible for the preparation and presentation of the Interim Separate Financial Statements, ensuring that the Interim Separate Financial Statements give a true and fair view of the Company's financial position as at 30 June 2026, as well as the results its separate results of operations and its separate cash flows for the 06-month accounting period then ended of the Company. In preparing these Interim Separate financial statements, the Board of Management confirms that it has complied with the following requirements:

- Established and maintained internal controls that the Board of Management considers necessary to ensure that the Interim Separate Financial Statements are free from material misstatement, whether due to fraud or error;
- Selected appropriate accounting policies and applied them consistently;
- Made judgments and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been complied with, subject to any material departures disclosed and explained in the Interim Separate Financial Statements;
- Prepared and presented the Interim Separate Financial Statements in accordance with prevailing Vietnamese Accounting Standards, Vietnamese Accounting System for Enterprises, and the relevant statutory requirements applicable to the preparation and presentation of Interim Separate Financial Statements;
- Prepared the Interim Separate Financial Statements on a going concern basis unless it is inappropriate to presume that the Company will continue its business operations.

The Board of Management is responsible for ensuring that proper accounting records are maintained and preserved so as to fairly reflect the Company's financial position at any time and to provide a basis for the preparation of the Interim Separate Financial Statements in compliance with the current regulations of the State. Moreover, the Board of Management is also responsible for safeguarding the assets of the Company and for taking appropriate measures to prevent and detect fraud and other irregularities.

The Board of Management confirms that the Company has complied with Decree No. 155/2020/ND-CP dated 31 December 2020 of the Government detailing the implementation of a number of articles of the Law on Securities, and that the Company has not violated its information disclosure obligations as prescribed in Circular No. 96/2020/TT-BTC dated 16 November 2020 of the Ministry of Finance providing guidance on information disclosure on the securities market, and Circular No. 68/2024/TT-BTC dated 18 September 2024 amending and supplementing a number of articles of Circular No. 96/2020/TT-BTC.

REPORT OF THE BOARD OF MANAGEMENT (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

8. Statement by the Board of Management

The Board of Management confirms that the accompanying reviewed Interim Separate Financial Statements give a true and fair view of the financial position of the Company as at 30 June 2026, and of its operating results and cash flows for the six-month accounting period then ended, in accordance with the prevailing Vietnamese Accounting Standards, Vietnamese Accounting System for Enterprises, and the relevant statutory requirements applicable to the preparation and presentation of Interim Separate Financial Statements.

Ho Chi Minh, 28 August 2026

ON BEHALF OF THE BOARD OF MANAGEMENT

DIRECTOR

M.S.D.N: 3800237... C.T.C.P CÔNG TY CỔ PHẦN SẢN XUẤT KINH DOANH DƯỢC VÀ TRANG THIẾT BỊ Y TẾ VIỆT MỸ VIỆT NAM

DANG NHI NUONG

PKF - TTG

HEAD OFFICE
12A05, Vinaconex Diamond Tower,
459C Bach Mai Street, Bach Mai Ward,
Hanoi, Vietnam
Tel: +84 888 136 336
Email: info@pkf-ttg.com.vn
Website: pkf-ttg.com.vn

No: 19 /2026/BCSX-TTG

REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

To: **The Shareholders**
The Board of Directors and the Board of Management
American Vietnamese Biotech INC

We have reviewed the accompanying Interim Separate financial statements of American Vietnamese Biotech INC (hereinafter referred to as the "Company"), which were prepared on 28/08/2026, and comprise: the Interim Separate of Financial Position as at 30 June 2026, the Interim Separate Statement of Income, the Interim Separate Statement of Cash Flows for the six-month accounting period then ended, and the Notes to the Interim Separate Financial Statements, presented on pages 07 to pages 44.

These reviewed Interim Separate Financial Statements are not intended to present the financial position, results of operations or cash flows in accordance with accounting principles and practices generally accepted in countries and jurisdictions other than Vietnam.

Responsibility of the Board of Management

The Board of Management is responsible for the preparation and fair presentation of the Company's Interim Separate Financial Statements in accordance with prevailing Vietnamese Accounting Standards, Vietnamese Accounting System for Enterprises, and the relevant statutory requirements applicable to the preparation and presentation of Interim Separate Financial Statements, and for such internal control as the Board of Management determines is necessary to enable the preparation and presentation of Interim Separate Financial Statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express a conclusion on these Interim Separate Financial Statements based on our review. We conducted our review in accordance with Vietnamese Standard on Review Engagements No. 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity.

A review of Interim Separate financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Auditor's conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Interim Separate Financial Statements do not give a true and fair view, in all material respects, of the separate financial position of American Vietnamese Biotech INC as at 30 June 2026, and of its separate results of operations and separate cash flows for the six-month accounting period then ended, in accordance with prevailing Vietnamese Accounting Standards, Vietnamese Accounting System for Enterprises, and the relevant statutory requirements applicable to the preparation and presentation of Interim Separate Financial Statements.

Other matter

The Company's Separate Financial Statements for the financial year ended 31 December 2025 were audited by International Auditing and Valuation Company Limited, which issued an unmodified opinion on those Separate Financial Statements on 15 May 2026. The Company's Interim Separate Financial Statements for the accounting period from 01 January 2025 to 30 June 2025 were reviewed by Nhan Tam Viet Auditing Company Limited, which issued a qualified conclusion on those Interim Separate Financial Statements on 28 August 2025.

Hanoi, 28 August 2026

FOR AND ON BEHALF OF
PKF-TTG AUDITING AND CONSULTING COMPANY LIMITED

Nguyen Hong Quang
Deputy General Director

Certificate of Registration for Audit Practice
No. 0576-2023-330-1

INTERRIM SEPARATE STATEMENT OF FINANCIAL POSITION

As at 30 June 2026

Unit: VND

ASSETS	Codes	Notes	30 Jun 2026	01 Jan 2026 (Reclassified)
CURRENT ASSETS	100		272.946.795.389	99.882.090.206
Cash and cash equivalents	**110**	**5.1**	**1.210.948.406**	**1.972.095.736**
Cash	111		1.210.948.406	1.972.095.736
Short-term financial investments	**120**		-	-
Short-term receivables	**130**		**233.774.642.200**	**81.433.710.997**
Short-term receivables from customers	131	5.3	23.389.694.937	18.793.097.280
Short-term advances to suppliers	132	5.4	177.265.543.369	17.757.003.704
Others short-term receivables	135	5.5	33.378.729.022	45.142.935.141
Allowance for doubtful short-term receivables (*)	136		(259.325.128)	(259.325.128)
Inventories	**140**	**5.7**	**36.983.739.869**	**16.284.033.892**
Inventories	141		36.983.739.869	16.284.033.892
Allowance for inventory write-down (*)	149		-	-
Short-term biological assets	**150**		-	-
Others short-term assets	**160**		**977.464.914**	**192.249.581**
Short-term prepaid expenses	161	5.11	121.888.124	90.482.526
Deductible value-added tax (VAT)	162		855.576.790	95.603.627
Taxes and other receivables from the State	163	5.14	-	6.163.428
NON-CURRENT ASSETS	200		1.480.931.915.151	1.526.680.849.490
Long-term receivables	**210**		**114.227.000.000**	**125.727.000.000**
Other long-term receivables	215	5.5	114.227.000.000	125.727.000.000
Fixed assets	**220**		**60.882.983.131**	**59.898.270.445**
Tangible fixed assets	221	5.9	24.853.243.009	27.087.910.847
- Cost	222		55.160.790.809	54.860.290.809
- Accumulated depreciation (*)	223		(30.307.547.800)	(27.772.379.962)
Intangible fixed assets	227	5.10	36.029.740.122	32.810.359.598
- Cost	228		66.064.921.722	59.564.895.987
- Accumulated amortization (*)	229		(30.035.181.600)	(26.754.536.389)
Long-term biological assets	**230**		-	-
Investment properties	**240**		-	-
Long-term work in progress	**250**		**13.848.339.735**	**20.691.865.470**
Long-term production and business costs in progress	251		-	-
Construction in progress	252	5.8	13.848.339.735	20.691.865.470
Long-term financial investments	**260**	**5.2**	**1.291.955.423.535**	**1.320.338.277.325**
Investments in subsidiaries	261		1.254.740.000.000	1.254.740.000.000
Investments in joint ventures and associates	262		153.300.000.000	153.300.000.000
Allowance for impairment of long-term equity investments in other entities (*)	264		(116.084.576.465)	(87.701.722.675)
Other non-current assets	**270**		**18.168.750**	**25.436.250**
Long-term prepaid expenses	271	5.11	18.168.750	25.436.250
TOTAL ASSETS	**280**		**1.753.878.710.540**	**1.626.562.939.696**

AMERICAN VIETNAMESE BIOTECH INC
Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

Form No. B 01 - DN
(Attached to Circular No. 99/2025/TT-BTC dated 27 October 2025 of the Minister of Finance)

INTERRIM SEPARATE STATEMENT OF FINANCIAL POSITION (CONTINUED)
As at 30 June 2026

RESOURCES	Codes	Notes	30 Jun 2026	01 Jan 2026 (Reclassified)
LIBIALITIES	**300**		**294.111.220.040**	**124.569.205.721**
Current liabilities	**310**		**290.111.220.040**	**124.569.205.721**
Short-term trade payables	311	5.13	22.257.001.116	917.335.164
Dividends and profits payable	313	5.15	75.924.090.000	75.924.090.000
Short-term taxes and other payables to the State	314	5.14	15.983.626	29.144.742
Employee payables	315		314.999.227	562.519.653
Short-term accrued expenses	316	5.16	34.886.183.344	23.968.555.935
Other short-term payables	320	5.17	86.866.900	41.464.400
Short-term borrowings and finance lease liabilities	321	5.12	156.626.095.827	23.126.095.827
Long-term liabilities	**330**		**4.000.000.000**	-
Long-term borrowings and finance lease liabilities	339	5.12	4.000.000.000	-
EQUITY	**400**	**5.18**	**1.459.767.490.500**	**1.501.993.733.975**
Owners' contributed capital	411		1.311.056.500.000	1.311.056.500.000
- Ordinary shares with voting rights	411a		1.311.056.500.000	1.311.056.500.000
Share premium	412		(395.300.000)	(395.300.000)
Retained earnings	420		149.106.290.500	191.332.533.975
- Retained earnings accumulated up to the end of the previous period	420a		191.332.533.975	234.243.514.791
- Retained earnings for the current period	420b		(42.226.243.475)	(42.910.980.816)
TOTAL RESOURCES	**440**		**1.753.878.710.540**	**1.626.562.939.696**

Ho Chi Minh, 28 August 2026

PREPARED BY	CHIEF ACCOUNTANT	DIRECTOR
TRAN HANG NGA	NGUYEN THU HUYEN	DANG NHI NUONG

M.S.D.N: 3800 ... CÔNG TY CỔ PHẦN SẢN XUẤT KINH DOANH DƯỢC VÀ TRANG THIẾT BỊ Y TẾ VIỆT MỸ * VIỆT NAM *

AMERICAN VIETNAMESE BIOTECH INC
Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

Form No. B 02 - DN
(Attached to Circular No. 99/2025/TT-BTC dated 27 October 2025 of the Minister of Finance)

INTERRIM SEPARATE INCOME STATEMENT

For the accounting period from 01 January 2026 to 30 June 2026

Unit: VND

ITEMS	Codes	Notes	From 01 Jan 2026 To 30 Jun 2026	From 01 Jan 2025 To 30 Jun 2025
Revenue from sales of goods and	**01**	**6.1**	**11.132.161.822**	**6.427.336.856**
Revenue deductions	02	6.2	19.186.667	-
Net revenue from sales of goods and rendering of services	**10**		**11.112.975.155**	**6.427.336.856**
Cost of sales	11	6.3	10.552.887.816	7.366.727.194
Gross profit from sales of goods and rendering of services	**20**		**560.087.339**	**(939.390.338)**
Gain/loss from the sale and disposal of investment property	21		-	-
Finance income	22	6.4	236.324	17.009.703.732
Finance costs	23	6.5	39.582.618.187	22.735.891.563
- Of which: Borrowing costs	24		11.199.764.397	2.293.791.366
Selling expenses	25	6.8	-	135.413.326
General and administrative expenses	26	6.8	3.195.339.481	3.691.974.670
Net profit from operating activities	**30**		**(42.217.634.005)**	**(10.492.966.165)**
Other income	31	6.6	601	140.217.607
Other expenses	32	6.7	8.610.071	42.395.941
Other profit	**40**		**(8.609.470)**	**97.821.666**
Total accounting profit before tax	**50**		**(42.226.243.475)**	**(10.395.144.499)**
Current corporate income tax expense	51	6.9	-	-
Deferred corporate income tax expense	52	6.9	-	-
Profit after corporate income tax	**60**		**(42.226.243.475)**	**(10.395.144.499)**

Ho Chi Minh, 28 August 2026

PREPARED BY	CHIEF ACCOUNTANT	DIRECTOR
TRAN HANG NGA	NGUYEN THU HUYEN	DANG NHI NUONG

M.S.D.N: 38002... CÔNG TY CỔ PHẦN SẢN XUẤT KINH DOANH DƯỢC VÀ TRANG THIẾT BỊ Y TẾ VIỆT MỸ VIỆT NAM

AMERICAN VIETNAMESE BIOTECH INC
Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

Form No. B 03 - DN
(Attached to Circular No. 99/2025/TT-BTC dated 27 October 2025 of the Minister of Finance)

INTERRIM SEPARATE CASH FLOW STATEMENT
(Indirect method)
For the accounting period from 01 January 2026 to 30 June 2026

Unit: VND

ITEMS	Codes	Notes	From 01 Jan 2026 To 30 Jun 2026	From 01 Jan 2025 To 30 Jun 2025
CASH FLOWS FROM OPERATING ACTIVITIES				
Profit before tax	**01**		**(42.226.243.475)**	**(10.395.144.499)**
Adjustments for:				
- Depreciation and amortization	02		5.815.813.049	5.277.338.239
- Provisions	03		28.382.853.790	20.442.100.197
- Gains/losses from investing and financing activities	05		-	(17.149.703.732)
- Borrowing costs	06		11.199.764.397	2.293.791.366
Operating profit before changes in working capital	**08**		**3.172.187.761**	**468.381.571**
- Increase/decrease in receivables	09		(141.594.740.938)	148.739.998.859
- Increase/decrease in inventories	10		(20.699.705.977)	(4.264.420.493)
- Increase/decrease in payables (excluding interest payable and corporate income tax payable)	11		21.167.386.910	(882.007.653)
- Increase/decrease in prepaid expenses	12		(24.138.098)	(135.942.252)
- Interest paid	14		(282.136.988)	-
Net cash flows from operating activities	**20**		**(138.261.147.330)**	**143.926.010.032**
CASH FLOWS FROM INVESTING ACTIVITIES				
Proceeds from collection of loans granted and disposal of debt instruments of other entities	24		-	500.000.000
Payments for equity investments in other entities	25		-	(204.227.000.000)
Proceeds from disposal of equity investments in other entities	26		-	40.900.000.000
Interest, dividends and profit distributions received	27		-	22.009.703.732
Net cash flows from investing activities	**30**		**-**	**(140.817.296.268)**
CASH FLOWS FROM FINANCING ACTIVITIES				
Proceeds from borrowings	33	7.1	137.500.000.000	-
Repayment of borrowings	34		-	(1.499.000.000)
Net cash flows from financing activities	**40**		**137.500.000.000**	**(1.499.000.000)**
Net increase/(decrease) in cash and cash	**50**		**(761.147.330)**	**1.609.713.764**
Cash and cash equivalents at the beginning of the period	**60**		**1.972.095.736**	**2.123.348.100**
Effects of exchange rate changes on cash and cash equivalents	61		-	-
Cash and cash equivalents at the end of the period	**70**		**1.210.948.406**	**3.733.061.864**

Ho Chi Minh, 28 August 2026

PREPARED BY	CHIEF ACCOUNTANT	DIRECTOR
TRAN HANG NGA	NGUYEN THU HUYEN	DANG NHI NUONG

CÔNG TY CỔ PHẦN SẢN XUẤT KINH DOANH DƯỢC VÀ TRANG THIẾT BỊ Y TẾ VIỆT MỸ

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS

For the accounting period from 01 January 2026 to 30 June 2026

1. THE COMPANY'S OPERATING CHARACTERISTICS

1.1. Form of ownership

American Vietnamese Biotech INC (hereinafter referred to as the "Company") is a joint stock company incorporated and operating in Vietnam under Business Registration Certificate No. 3800237998, initially issued on 26 August 2002, and as amended for the 24th time on 17 August 2025, issued by the Department of Finance of Ho Chi Minh City.

The Company's head office is located at: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City.

The Company's actual contributed charter capital according to its Business Registration Certificate as at 30 June 2026 is VND 1,311,056,500,000 VND divided into 131,105,650 shares with a par value of VND 10.000 per share.

1.2. Principal activities

The Company operates in the business sector of trading medical equipment and diagnostic reagents.

1.3. Business lines

During the period, the Company had the following activities:

- Retail sale of pharmaceuticals, medical equipment, cosmetics and toilet articles in specialized stores. Details: Trading in pharmaceuticals, purchase and sale of medical equipment, instruments, and diagnostic reagents;
- Manufacture of medical, dental, orthopedic, and rehabilitation equipment and instruments;
- Details: Manufacture of medical diagnostic instruments;
- Manufacture of basic pharmaceutical products, pharmaceutical preparations, and botanical products. Details: Manufacture and trading of vaccines and biological products;
- Manufacture of cosmetics, soap, detergents, cleaning and polishing preparations, and toilet preparations; Agents, brokers, and auctions. Details: Consignment agency, manufacture of plastic products;
- Real estate activities with own, leased, or rented property. Details: Real estate trading;
- Water collection, treatment, and supply; Sewerage and wastewater treatment; Waste recycling; Remediation activities and other waste management services;
- Other professional, scientific, and technical activities not elsewhere classified. Details: Technology transfer in other business sectors as specified in the Business Registration Certificate;

Principal business activity: Trading in medical equipment and diagnostic reagents.

1.4. Normal operating cycle

The Company's normal operating cycle is completed within 12 months.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

1.5. Corporate structure

The Company's head office is located at: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City.

As at 30 June 2026, American Vietnamese Biotech INC has direct investments in 13 subsidiaries, 13 associates, and 02 dependent accounting units, detailed as follows:

Subsidiaries:

No.	Company Name	Head Office Address	Ownership Interest	Voting Rights	Principal Activities
1	Viet My Hospital Investment JSC	No. 307 Nguyen Du Extended Street, Nong Trang Ward, Phu Tho Province, Vietnam.	83.33%	83.33%	Pharma wholesale; machinery and medical equipment wholesal
2	Ha Long Kyoto Technology Development JSC	Lot A15, Nam Son Industrial Cluster, Ba Che Commune, Quang Ninh Province, Vietnam.	99.00%	99.00%	Pharma production; manufacture of ovens, furnaces, and furnace burners
3	Golab Uong Bi Testing Center JSC	Group 4, Zone 4, Bai Chay Ward, Quang Ninh Province.	98.00%	98.00%	Polyclinics, specialty clinics
4	Song Hau New Technology Application Research JSC	Song Hau Industrial Park - Phase 1, Chau Thanh District, Can Tho City, Vietnam.	98.00%	98.00%	Manufacture of ovens, furnaces, and furnace burners
5	Ha Dong Clinic JSC	3rd Floor, No. 1 Phuc Thinh, Buou Bridge, Kien Hung Ward, Ha Noi City, Vietnam.	98.00%	98.00%	Polyclinics, specialty clinics, and dental clinics
6	Hoa Binh Clinic JSC	1st Floor, No. 83 Cu Chinh Lan Street, Group 13, Hoa Binh Ward, Phu Tho Province, Vietnam.	98.00%	98.00%	Polyclinics, specialty clinics, and dental clinics
7	Viet Tri Clinic JSC	No. 307 Nguyen Du Extended Street, Nong Trang Ward, Phu Tho Province, Vietnam.	98.00%	98.00%	Polyclinics, specialty clinics, and dental clinics
8	Gia Lam High-Tech Clinic JSC	18 BT5, Phap Van - Tu Hiep Urban Area, Yen So Ward, Hanoi City, Vietnam	98.00%	98.00%	Polyclinics, specialty clinics, and dental clinics
9	Medicare Can Tho Clinic JSC	No. 408 Nguyen Van Cu Street, An Binh Ward, Can Tho City, Vietnam.	98.00%	98.00%	Polyclinics, specialty clinics, and dental clinics

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

No.	Company Name	Head Office Address	Ownership Interest	Voting Rights	Principal Activities
10	Medicare Hau Giang Clinic JSC	No. 16, 1st Floor, Street No. 14, Area 4, Vi Thanh Ward, Can Tho City, Vietnam.	98.00%	98.00%	Polyclinics, specialty clinics, and dental clinics
11	Medicare Soc Trang Clinic JSC	1st Floor, No. 438 Le Duan Street, Hamlet 4, Phu Loi Ward, Can Tho City, Vietnam.	98.00%	98.00%	Polyclinics, specialty clinics, and dental clinics
12	Golab Nga Bay Testing Center JSC	No. 222, 30/4 Street, Area 5, Nga Bay Ward, Can Tho City.	98.00%	98.00%	Polyclinics, specialty clinics, and dental clinics
13	Leopard Solutions JSC	No. 34, Street 79, Dinh Hamlet, Cu Chi Commune, Ho Chi Minh City.	75.00%	75.00%	Computer programming

Associates:

No.	Company Name	Head Office Address	Ownership Interest (%)	Voting Rights (%)	Principal Activities
1	Medicare Huu Nghi Clinic JSC	No. 179 Giai Phong Street, Bach Mai Ward, Ha Noi City	49%	49%	Polyclinics, specialty clinics, and dental clinics
2	Nghe An Clinic JSC	1st Floor, No. 68 Ho Tong Thoc Street, Block 13, Vinh Phu Ward, Nghe An Province	35%	35%	Polyclinics, specialty clinics, and dental clinics
3	Ba Dinh Clinic JSC	No. 37A Doc Phu San, De La Thanh Street, Lang Ward, Ha Noi City	49%	49%	Polyclinics, specialty clinics, and dental clinics
4	Golab Go Vap Testing Center JSC	1st Floor, Lot BT 5, No. 18 Phap Van - Tu Hiep New Urban Area, Yen So Ward, Ha Noi City	35%	35%	Polyclinics, specialty clinics, and dental clinics
5	Golab Go Vap Testing Center JSC	1st Floor, No. 178 Nguyen Thai Son, Hanh Thong Ward, Ho Chi Minh City	35%	35%	Polyclinics, specialty clinics, and dental clinics
6	Golab Bac Lieu Testing Center JSC	Ground Floor, No. 210 Ba Trieu Street, Bac Lieu Ward, Ca Mau Province	35%	35%	Polyclinics, specialty clinics, and dental clinics
7	Golab Tien Giang Testing Center JSC	368A, Phuoc Hoa Hamlet, Trung An Ward, Dong Thap Province	35%	35%	Polyclinics, specialty clinics, and dental clinics

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

No.	Company Name	Head Office Address	Ownership Interest (%)	Voting Rights (%)	Principal Activities
8	Golab Binh Duong Testing Center JSC	634 Binh Duong Boulevard, Zone 5, Phu Loi Ward, Ho Chi Minh City	35%	35%	Polyclinics, specialty clinics, and dental clinics
9	Golab Ha Giang Testing Center JSC	1st Floor, No. 75D Nguyen Thai Hoc Street, Group 16, Ha Giang 2 Ward, Tuyen Quang	49%	49%	Polyclinics, specialty clinics, and dental clinics
10	Golab Ninh Binh Testing Center JSC	1st Floor, House No. 140, Tue Tinh Street, Hoa Lu Ward, Ninh Binh City	49%	49%	Polyclinics, specialty clinics, and dental clinics
11	Golab Vung Tau Testing Center JSC	No. 745 Vo Van Kiet, Tam Long Ward, Ho Chi Minh City	49%	49%	Polyclinics, specialty clinics, and dental clinics
12	Famicare Phap Van JSC	1st Floor, Lot BT 5, No. 17 Phap Van - Tu Hiep New Urban Area, Yen So Ward, Ha Noi City	35%	35%	Polyclinics, specialty clinics, and dental clinics
13	Famicare Tuyen Quang JSC	2nd Floor, No. 23, Hoa Lu Street, Group 01, Minh Xuan Ward, Tuyen Quang Province	35%	35%	Polyclinics, specialty clinics, and dental clinics

Dependent Accounting Units:

No.	Company Name	Head Office Address	Principal Activities
1	Representative Office of American Vietnamese Biotech INC	A30-A31 D1 Street, Tan Hai Minh Residential Area, Quarter 1, Thu Duc Ward, Ho Chi Minh City	Pharmaceuticals trading; medical equipment, instruments & diagnostic reagents
2	Branch of American Vietnamese Biotech INC	Vinaconex Diamond Building, No. 459 C Bach Mai, Bach Mai Ward, Ha Noi City, Vietnam	Pharmaceuticals trading; medical equipment, instruments & diagnostic reagents

1.6. Number of employees

The total number of employees of the Company as at June 30, 2026 was 23 persons (as at December 31, 2025: 28 persons).

2. ACCOUNTING PERIOD AND ACCOUNTING CURRENCY

The Company's annual accounting period begins on 01 January and ends on 31 December of the calendar year.

These Interim Separate Financial Statements have been prepared for the accounting period from 01 January 2026 to 30 June 2026.

The accounting currency used by the Company is the Vietnam Dong ("VND").

3. ACCOUNTING STANDARDS AND ACCOUNTING SYSTEM

3.1. Accounting Standards and Accounting System applied

The Company applies the Vietnamese Accounting Standards, Vietnamese Accounting System for Enterprises, and the relevant statutory requirements applicable to the preparation and presentation of Interim Separate Financial Statements.

Accordingly, these Interim Separate Financial Statements are not intended to present the Company's financial position, results of operations or cash flows in accordance with accounting principles and practices generally accepted in countries and jurisdictions other than Vietnam..

3.2. Adoption of new Guidance on the Accounting System for Enterprices

On 27 October 2025, the Ministry of Finance issued Circular No. 99/2025/TT-BTC ("Circular 99") providing guidance on the corporate accounting system. Circular 99 became effective on 01 January 2026 and applies to financial years beginning on or after 01 January 2026. Circular 99 supersedes the following regulations:

- Circular No. 200/2014/TT-BTC dated 22 December 2014 of the Ministry of Finance ("Circular 200") providing guidance on the corporate accounting system;
- Circular No. 75/2015/TT-BTC dated 18 May 2015 of the Ministry of Finance amending Article 128 of Circular 200;
- Circular No. 53/2016/TT-BTC dated 21 March 2016 of the Ministry of Finance amending and supplementing a number of articles of Circular 200.

Based on the assessment of the Board of Management, the adoption of Circular 99 during the current accounting period has no material impact on the Company's Interim Separate Financial Statements.

3.3. Statement of compliance with Vietnamese Accounting Standards and Accounting System

The Board of Management confirms that the Company has fully complied with the requirements of prevailing Vietnamese Accounting Standards, Vietnamese Accounting System for Enterprises, and the relevant statutory requirements applicable to the preparation and presentation of Interim Separate Financial Statements.

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The following are the significant accounting policies adopted by the Company in the preparation and presentation of these Interim Separate Financial Statements.

The accounting policies adopted in the preparation and presentation of these Interim Separate Financial Statements are consistent with those applied in the preparation and presentation of the Company's most recent annual Financial Statements, except as disclosed in Note 3.2.

4.1. Accounting estimates

The preparation and presentation of the Interim Separate Financial Statements in conformity with prevailing Vietnamese Accounting Standards, Vietnamese Accounting System for Enterprises, and the relevant statutory requirements applicable to the preparation and presentation of Interim Separate Financial Statements require the Board of Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the end of the accounting period, as well as the reported amounts of revenues and expenses during the accounting period.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

Significant estimates and assumptions used in these Interim Separate Financial Statements include:

- Allowance for doubtful receivables;
- Allowance for inventory write-down;
- Estimates relating to the allocation of prepaid expenses;
- Useful lives of property, plant and equipment;
- Corporate income tax estimates;

These estimates and assumptions are regularly evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances and that may materially affect the Company's Interim Separate Financial Statements. Actual results may differ from these estimates and assumptions.

4.2. Cash and cash equivalents

Cash comprises cash on hand and demand deposits with banks.

Cash equivalents are short-term investments with an original maturity or remaining term to maturity of three months or less from the date of acquisition that are readily convertible into known amounts of cash and are subject to an insignificant risk of changes in value.

4.3. Financial investments

Held-to-maturity investments

Held-to-maturity investments comprise investments that the Company has the positive intent and ability to hold until maturity. Held-to-maturity investments include term deposits at banks and loans held-to-maturity.

Held-to-maturity investments are initially recognized at cost. After initial recognition, these investments are stated at recoverable amount. Interest income from held-to-maturity investments post-acquisition is recognized in the income statement on an accrual basis. Interest earned prior to the acquisition date is deducted from the initial cost of investment at the acquisition date.

When there is objective evidence that part or all of the investment may not be recoverable, the impairment loss is recognized in financial expenses in the year and directly reduces the carrying amount of the investment.

Investments in subsidiaries, joint ventures, and associates

Subsidiaries are entities over which the Company has the power to govern the financial and operating policies, generally accompanying a shareholding of more than half of the voting rights. The assessment of control considers the existence and effect of potential voting rights currently exercisable or convertible.

Associates are entities over which the Company has significant influence, but not control, over the financial and operating policies of the entity. Joint ventures are entities over which the Company has joint control established by contractual agreement, requiring unanimous consent of the joint venture parties for strategic financial and operating decisions. Joint ventures and associates are typically entities in which the Company holds between 20% and 50% of the voting rights.

Investments in subsidiaries, joint ventures, and associates are initially recognized at cost, including purchase price and directly attributable transaction costs. After initial recognition, these investments are carried at cost less allowance for impairment. Allowance for impairment of investments is made when the investee incurs losses that may result in the Company losing its capital, unless there is evidence that the investment value is not impaired. The impairment allowance is reversed when the investee subsequently generates profits to offset the previously provisioned losses. The reversal is limited so that the carrying amount of the investment does not exceed the carrying amount that would have been determined had no impairment allowance been recognized.

In the event that the Company liquidates a subsidiary and merges all assets and liabilities of the subsidiary into the Company (where the Company inherits all rights and obligations of the subsidiary), the Company derecognizes the carrying amount of the investment in the subsidiary and recognizes all assets and liabilities of the dissolved subsidiary in the Company's separate financial statements at fair value as of the merger date. The difference between the carrying amount of the investment in the subsidiary and the net fair value of assets and liabilities acquired is recognized in financial income or financial expenses.

Other investments

Other investments are initially recognized at cost, including investments in equity instruments of other entities where the Company has neither control, joint control, nor significant influence over the investee; investments in Business Cooperation Contracts (BCC) where the entity does not have joint control but is entitled to benefits based on post-tax profits of the BCC; precious metals and gemstones not used as raw materials for production or purchased - sold as trading goods; and paintings, photos, documents, or collectibles not participating in ordinary operating activities.

When there is objective evidence that these investments have suffered a decline below market value, and the impairment amount can be measured reliably, the entity reduces the carrying amount of the investment and recognizes the loss in financial expenses.

4.4. Trade receivables

Receivables presented in the Interim Separate Financial Statements are carried at the amounts due from customers and other receivables, less the allowance for doubtful receivables at the reporting date:

- Receivables expected to be recovered or settled within one year (or within the normal operating cycle) are classified as current assets;
- Receivables expected to be recovered or settled after more than one year (or beyond the normal operating cycle) are classified as non-current assets.

The allowance for doubtful receivables represents the estimated losses arising from receivables outstanding at the end of the accounting period that are unlikely to be collected.

The allowance for doubtful receivables is recognized for receivables that have been overdue for more than six months, or for receivables where debtors are unlikely to settle their obligations due to liquidation, bankruptcy, or similar financial difficulties.

4.5. Inventories

Inventories are stated at the lower of cost and net realisable value.

The cost of inventories comprises purchase costs, conversion costs and other directly attributable costs incurred in bringing the inventories to their present location and condition.

The net realisable value of inventories is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

The Company accounts for inventories under the transaction-by-transaction basis. The cost of inventories is determined using the following methods:

- Raw materials, tools and supplies, and merchandise   Weighted average cost

An allowance for inventory write-down is recognised for inventories whose cost exceeds their net realisable value in accordance with Vietnamese Accounting Standard No. 02 - Inventories, Circular No. 48/2019/TT-BTC dated 08 August 2019 of the Ministry of Finance providing guidance on the recognition and treatment of allowances for inventory write-downs, investment losses, doubtful receivables, and warranties for products, goods, services and construction works at enterprises.

4.6. Fixed assets and depreciation/amortization

Fixed assets are stated at historical cost less accumulated depreciation/amortization.

Tangible fixed assets

The cost of an item of tangible fixed asset comprises its purchase price and any directly attributable costs incurred in bringing the asset to its intended working condition for its intended use. The cost of self-constructed tangible fixed asset comprises construction costs, actual production costs incurred, together with installation and trial-run costs. Subsequent expenditure incurred to upgrade tangible fixed asset is capitalised and added to the carrying amount of the asset. Expenditure on repairs and maintenance is recognised in the Statement of Income when incurred. Upon disposal or retirement of tangible fixed asset, the cost and accumulated depreciation are derecognised, and any resulting gain or loss is recognised in the Statement of Income.

Depreciation of tangible fixed asset is calculated using the straight-line method over the estimated useful lives of the respective assets. The depreciation rates are determined to allocate the cost of the assets over their estimated useful lives and are in accordance with the guidance provided in Circular No. 45/2013/TT-BTC dated 25 April 2013 of the Ministry of Finance on the management, use and depreciation of fixed assets, Circular No. 147/2016/TT-BTC dated 13 October 2016 amending and supplementing a number of articles of Circular No. 45/2013/TT-BTC, and Circular No. 28/2017/TT-BTC dated 12 April 2017 amending and supplementing a number of articles of Circular No. 45/2013/TT-BTC, Circular No. 30/2025/TT-BTC dated 30 May 2025 amending and supplementing a number of articles of Circular No. 45/2013/TT-BTC.

The estimated useful lives of the Company's tangible fixed asset are as follows:

- Machinery and equipment: 06 - 10 years
- Motor vehicles and transmission equipment: 05 - 10 years

Intangible fixed assets

The historical cost of intangible fixed assets comprises their purchase price and any directly attributable expenses incurred in preparing the assets for their intended use. Costs of upgrading intangible fixed assets are capitalized into the historical cost; other expenses are charged to business operations during the period. When intangible fixed assets are sold or disposed of, their historical cost and accumulated amortization are derecognized, and any resulting gain or loss from disposal is recognized in the statement of income.

Amortization of intangible fixed assets is calculated on a straight-line basis, applied to assets at rates calculated to allocate their historical cost over their estimated useful lives. The amortization of intangible fixed assets complies with the guidance in Circular No. 45/2013/TT-BTC dated 25 April 2013 issued by the Ministry of Finance guiding the management, use, and depreciation/amortization of fixed assets; Circular No. 147/2016/TT-BTC dated 13 October 2016 amending and supplementing certain articles of Circular No. 45/2013/TT-BTC; and Circular No. 28/2017/TT-BTC dated 12 April 2017 amending and supplementing certain articles of Circular No. 45/2013/TT-BTC. 30/2025/TT-BTC dated 30 May 2025 amending and supplementing a number of articles of Circular No. 45/2013/TT-BTC.

The estimated useful lives of intangible fixed assets of the Company are as follows:

- Computer software: 04 years

4.7. Business Cooperation Contracts

A Business Cooperation Contract (BCC) is a contractual agreement between two or more parties to carry out economic activities jointly without establishing a separate legal entity. These activities may be jointly controlled, non-jointly controlled by the contributing parties, or controlled by one of the participating parties.

A BCC may be executed in the form of jointly constructing assets or cooperating in certain business operations. Participating parties in a BCC may agree to share revenues, share products, share post-tax profits based on the operating results of the BCC, or receive fixed profits regardless of the BCC's operating results.

In all cases, upon receiving cash or assets contributed by other parties for the BCC, the receiving party must account for them as liabilities and must not recognize them in owners' equity.

4.8. Prepaid expenses

Prepaid expenses include office repair and decoration expenses, as well as other short-term and long-term prepaid expenses. The allocation of prepaid expenses into production and operating expenses for each period is based on the nature and magnitude of each expense item, corresponding to its ability to generate economic benefits.

4.9. Trade payables and other payables

Trade payables and other payables are presented in the Interim Separate Financial Statements at the carrying amounts payable to suppliers and other creditors and are detailed by individual creditor. At the reporting, if:

- Payables due within one year (or within the normal operating cycle) are classified as current liabilities;
- Payables due after more than one year (or beyond the normal operating cycle) are classified as non-current liabilities;

4.10. Dividends and profit distribution payable

Profit after corporate income tax is distributed to the shareholders after appropriations to the funds in accordance with the Company's Charter, the applicable laws and regulations, and the resolution of the General Meeting of Shareholders

Dividends are declared from retained earnings based on each shareholder's ownership interest and are recognised as a liability when approved by the General Meeting of Shareholders.

4.11. Accrued expenses

Accrued expenses represent expenses that have been recognised in operating expenses during the accounting period but have not yet been paid as at the end of the accounting period. When such expenses are actually incurred, any difference between the accrued amount and the actual amount is recognised by recording an additional expense or reversing the excess accrual, as appropriate.

4.12. Borrowing costs and capitalisation of borrowing costs

Borrowing costs comprise interest expense and other costs incurred in connection with borrowings. Such costs are recognised as finance costs in the accounting period, except where they are directly attributable to the acquisition, construction or production of qualifying assets, in which case they are capitalised as part of the cost of those assets in accordance with the accounting standard on borrowing costs.

The capitalisation of borrowing costs is suspended during extended periods in which the construction or production of a qualifying asset is interrupted, unless such interruption is a necessary part of the process of preparing the asset for its intended use or sale. Capitalisation ceases when substantially all the activities necessary to prepare the qualifying asset for its intended use or sale have been completed. Borrowing costs incurred thereafter are recognised as finance costs in the accounting period.

The amount of borrowing costs capitalised during an accounting period shall not exceed the total borrowing costs incurred during that period. The amount of interest expense and the amortisation of discounts or premiums capitalised in each accounting period shall not exceed the actual interest expense incurred and the related amortisation recognised during that period.

4.13. Owners' equity

The initial invested capital of the Company is recognised at the value of the capital contributions made by the shareholders upon conversion into, or establishment of, the joint stock company. During the course of operations, the Company's invested capital is increased by additional capital contributions from shareholders.

Share premium is recognised as the difference between the reissue price and the par value of shares issued on initial or subsequent share issuances, the difference between the reissue price and the carrying amount of treasury shares, and the equity component of convertible bonds upon maturity. Direct costs attributable to additional share issuances and the reissue of treasury shares are deducted from share premium.

When the Company repurchases its own shares, the consideration paid, including directly attributable transaction costs, is recognised as treasury shares and presented as a deduction from owners' equity. Upon reissue of treasury shares, the difference between the reissue price and the carrying amount of the treasury shares is recognised in Share Premium.

Profit after corporate income tax is distributed to the shareholders after appropriations to the funds in accordance with the Company's Charter, applicable laws and regulations, and the resolution of the General Meeting of Shareholders.

4.14. Taxes

Corporate income tax ("CIT"):

Taxable income is determined based on the results of operations for the accounting period and adjusted for expenses that are not deductible for tax purposes.

The Company's applicable corporate income tax rate for the accounting period is 20%.

Corporate income tax expense recognised during the accounting period comprises current corporate income tax expense.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

Current income tax is the amount of income tax payable based on taxable income for the period and the applicable tax rate. Taxable income differs from accounting profit because of adjustments for temporary differences between tax accounting and financial accounting, as well as adjustments for income that is not taxable and expenses that are not deductible for tax purposes.

Deferred income tax represents corporate income tax payable or recoverable in future periods arising from temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax liabilities are recognised for all taxable temporary differences. Deferred tax assets are recognised only to the extent that it is probable that future taxable profits will be available against which the deductible temporary differences can be utilised.

Other taxes: in accordance with current Vietnamese regulations

The Company's tax returns are subject to examination by the tax authorities. Because the application of tax laws and regulations to many types of transactions may be interpreted differently, the tax amounts presented in these Interim Financial Statements may subsequently be adjusted by the tax authorities.

4.15. Revenue

Revenue is recognised when the outcome of a transaction can be measured reliably and it is probable that the economic benefits associated with the transaction will flow to the Company.

(i) Revenue from the sale of goods is recognised when substantially all the risks and rewards of ownership of the goods have been transferred to the buyer, the Company retains neither continuing managerial involvement nor effective control over the goods sold, and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

(ii) Revenue from the rendering of services is recognised when substantially all the risks and rewards relating to the services have been transferred to the customer, the services have been rendered and accepted by the customer, and both the costs incurred and the costs to complete the service transaction can be measured reliably. Revenue from consulting services is recognised based on the value stated in the issued VAT invoices, the work completion acceptance minutes, and the customer's acceptance for payment.

(iii) Finance income comprises dividend income, profit distributions, interest income on deposits, foreign exchange gains, gains from deferred payment sales, and other finance income. Interest income is recognised on an accrual basis by reference to the outstanding deposit balances and the applicable interest rates. Foreign exchange gains and gains arising from customers' late payments are recognised based on the relevant contracts and confirmation minutes with customers. Dividend income and profit distributions are recognised when the Company's right to receive payment has been established. Share are recognised only by recording the additional number of shares received and no value is recognised for such shares.

4.16. Cost of sales

Cost of sales is recognised consistently with revenue from the sale of goods and the rendering of services and in accordance with the prudence principle.

Abnormal direct material costs, direct labour costs, and fixed manufacturing overheads that are not allocated to the cost of inventories are recognised immediately as cost of sales (after deducting any compensation received, if any), even if the related finished goods or merchandise have not yet been sold.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

4.17. Finance costs

The Company's finance costs comprise interest expenses on borrowings incurred during the accounting period in accordance with applicable accounting regulations.

4.18. Selling expenses and general and administrative expenses

Selling expenses and general and administrative expenses comprise all expenses actually incurred in connection with the sale of goods, the rendering of services, and the general administration of the Company.

4.19. Financial instruments

Initial recognition

Financial assets: Upon initial recognition, financial assets are recognised at cost plus transaction costs directly attributable to the acquisition of the financial assets.The Company's financial assets comprise cash, cash equivalents, trade receivables, other receivables, deposits, financial investments and derivative financial instruments.

Financial liabilities: Upon initial recognition, financial liabilities are recognised at cost plus transaction costs directly attributable to the issuance of the financial liabilities. The Company's financial liabilities comprise trade payables, other payables, accrued expenses, finance lease liabilities, borrowings and derivative financial instruments.

Subsequent measurement

Currently, there are no regulations governing the subsequent measurement of financial instruments after initial recognition under the applicable Vietnamese accounting regulations.

4.20. Related parties

Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial and operating policy decisions. Parties are considered to be related if:

- Enterprises, including parent companies, subsidiaries and associates, and individuals that, directly or indirectly through one or more intermediaries, control the Company, are controlled by the Company, or are under common control with the Company.
- Associates; individuals who, directly or indirectly, hold voting rights in the Company and have significant influence over the Company; key management personnel of the Company; close family members of such individuals or related parties; and entities controlled or significantly influenced by such individuals.

In considering each possible related party relationship, the substance of the relationship is considered rather than merely its legal form.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

5. ADDITIONAL INFORMATION FOR ITEMS PRESENTED IN THE INTERIM SEPARATE STATEMENT OF FINANCIAL POSITION

5.1. Cash and cash equivalents

		30 Jun 2026 (VND)	01 Jan 2026 (VND)
Cash on hand	(i)	884,419,235	581,800,202
Cash at banks	(ii)	326,529,171	1,390,295,534
Cash equivalents		-	-
Total		**1,210,948,406**	**1,972,095,736**

(i) Cash on hand balance as at the period end comprises:

	Original currency	VND
Foreign currency	-	-
Vietnamese Dong		884,419,235
Total		**884,419,235**

(ii) Cash at bank balance as at the period end comprises:

	Original currency	VND
Foreign currency	-	-
Vietnamese Dong		**326,529,171**
Vietnam Technological and Commercial Joint Stock Bank - Thang Long Branch		115,686,803
Tien Phong Commercial Joint Stock Bank - South Hanoi Branch		188,133,319
Other Banks		22,709,049
Total		**326,529,171**

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

5.2. Financial investments

a. Equity investments in other entities

	30 Jun 2026 (VND)			01 Jan 2026 (VND)		
	Cost	Recoverable Amount	Allowance Value	Cost	Recoverable Amount	Allowance Value
Investments in Subsidiaries	**1,254,740,000,000**	**1,157,966,973,273**	**(113,141,127,631)**	**1,254,740,000,000**	**1,169,483,810,637**	**(85,256,189,363)**
Viet My Hospital Investment JSC	*250,000,000,000*	*220,018,510,505*	*(29,982,688,803)*	*250,000,000,000*	*224,644,288,763*	*(25,355,711,237)*
Ha Long Kyoto Technology Development JSC	*108,900,000,000*	*97,454,202,237*	*(20,992,367,763)*	*108,900,000,000*	*97,571,847,432*	*(11,328,152,568)*
Golab Uong Bi Testing Center JSC	*49,000,000,000*	*39,412,578,155*	*(12,233,227,805)*	*49,000,000,000*	*40,776,022,640*	*(8,223,977,360)*
Song Hau New Technology Application Research JSC	*147,000,000,000*	*147,000,000,000*	-	*147,000,000,000*	*147,000,000,000*	
Hoa Binh Clinic JSC	*122,500,000,000*	*114,963,943,379*	*(5,509,358,599)*	*122,500,000,000*	*116,207,371,655*	*(6,292,628,345)*
Viet Tri Clinic JSC	*106,820,000,000*	*82,698,679,538*	*(4,800,680,621)*	*106,820,000,000*	*84,197,222,335*	*(22,622,777,665)*
Ha Dong Clinic JSC	*77,420,000,000*	*72,623,101,401*	*(23,876,320,462)*	*77,420,000,000*	*73,885,107,287*	*(3,534,892,713)*
Gia Lam High-Tech Clinic JSC	*77,420,000,000*	*72,968,788,299*	*(7,792,791,201)*	*77,420,000,000*	*73,122,626,333*	*(4,297,373,667)*
Medicare Can Tho Clinic JSC	*77,420,000,000*	*74,755,554,664*	*(3,858,339,384)*	*77,420,000,000*	*75,710,915,726*	*(1,709,084,274)*
Medicare Hau Giang Clinic JSC	*77,420,000,000*	*75,231,615,095*	*(4,095,352,993)*	*77,420,000,000*	*75,528,408,466*	*(1,891,591,534)*
Medicare Soc Trang Clinic JSC	*77,420,000,000*	*77,420,000,000*	-	*77,420,000,000*	*77,420,000,000*	
Golab Nga Bay Testing Center JSC	*77,420,000,000*	*77,420,000,000*	-	*77,420,000,000*	*77,420,000,000*	
Leopard Solutions JSC	*6,000,000,000*	*6,000,000,000*	-	*6,000,000,000*	*6,000,000,000*	

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

	30 Jun 2026 (VND)			01 Jan 2026 (VND)		
	Cost	Recoverable Amount	Allowance Value	Cost	Recoverable Amount	Allowance Value
Investments in Associates	**153,300,000,000**	**150,356,551,166**	**(2,943,448,834)**	**153,300,000,000**	**150,854,466,688**	**(2,445,533,312)**
Nghe An Clinic JSC	*10,500,000,000*	*10,323,636,009*	*(176,363,991)*	*10,500,000,000*	*10,371,197,860*	*(128,802,140)*
Ba Dinh Clinic JSC	*10,500,000,000*	*9,628,474,511*	*(871,525,489)*	*10,500,000,000*	*9,766,828,953*	*(733,171,047)*
Famicare Phap Van JSC	*10,500,000,000*	*10,429,043,808*	*(70,956,192)*	*10,500,000,000*	*10,438,267,649*	*(61,732,351)*
Famicare Tuyen Quang JSC	*10,500,000,000*	*10,428,690,980*	*(71,309,020)*	*10,500,000,000*	*10,441,376,882*	*(58,623,118)*
Golab Phap Van Testing Center JSC	*10,500,000,000*	*10,272,777,849*	*(227,222,151)*	*10,500,000,000*	*10,342,036,401*	*(157,963,599)*
Golab Go Vap Testing Center JSC	*10,500,000,000*	*10,404,961,076*	*(95,038,924)*	*10,500,000,000*	*10,410,545,374*	*(89,454,626)*
Golab Bac Lieu Testing Center JSC	*10,500,000,000*	*10,316,679,545*	*(183,320,455)*	*10,500,000,000*	*10,383,526,004*	*(116,473,996)*
Golab Binh Duong Testing Center JSC	*10,500,000,000*	*10,393,207,000*	*(106,793,000)*	*10,500,000,000*	*10,398,580,539*	*(101,419,461)*
Golab Tien Giang Testing Center JSC	*10,500,000,000*	*10,436,345,662*	*(63,654,338)*	*10,500,000,000*	*10,449,630,981*	*(50,369,019)*
Golab Ninh Binh Testing Center JSC	*14,700,000,000*	*14,441,582,126*	*(258,417,874)*	*14,700,000,000*	*14,506,328,779*	*(193,671,221)*
Golab Vung Tau Testing Center JSC	*14,700,000,000*	*14,264,525,033*	*(435,474,967)*	*14,700,000,000*	*14,275,605,456*	*(424,394,544)*
Golab Ha Giang Testing Center JSC	*14,700,000,000*	*14,596,546,384*	*(103,453,616)*	*14,700,000,000*	*14,621,850,350*	*(78,149,650)*
Medicare Huu Nghi Clinic JSC	*14,700,000,000*	*14,420,081,183*	*(279,918,817)*	*14,700,000,000*	*14,448,691,460*	*(251,308,540)*
Total	**1,408,040,000,000**	**1,308,323,524,439**	**(116.084.576.465)**	**1,408,040,000,000**	**1,320,338,277,325**	**(87,701,722,675)**

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

5.3. Trade receivables

		30 Jun 2026 (VND)		01 Jan 2026 (VND)	
		Carrying Amount	Allowance Vlaue	Carrying Amount	Allowance Value
a.	**Short-term trade receivables**	**23.389.694.937**	**(259.325.128)**	**18.793.097.280**	**(259.325.128)**
	Golab Hai Phong Testing Center JSC	1.120.000.000	-	1.120.000.000	-
	Golab Ben Tre Testing Center JSC	1.200.000.000	-	-	-
	Golab Vinh Yen Testing Center JSC	1.252.791.156	-	1.252.791.156	-
	Golab Ha Tinh Testing Center JSC	1.149.807.175	-	1.149.807.175	-
	Other trade receivables	18.667.096.606	(259.325.128)	15.270.498.949	(259.325.128)

b. **Trade receivables from related parties are detailed in Note 8.3.**

5.4. Prepayments to suppliers

	30 Jun 2026 (VND)		01 Jan 2026 (VND)	
	Carrying Amount	Allowance Value	Carrying Amount	Allowance Value
Short-term prepayments to suppliers	**177,265,543,369**	**-**	**17,757,003,704**	**-**
Lou Investment JSC	63,597,260,000	-	7,719,000,000	-
Kanpekhi Japan JSC	59,793,247,081	-	5,518,853,693	-
High-Tech Medical Environment Co., Ltd	27,957,000,000	-	3,430,000,000	-
Can Tho High Technical Investment JSC	27,957,000,000	-	-	-
Prepayments to other suppliers	3,978,036,288	-	1,089,150,011	-

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

5.5. Other receivables

		30 Jun 2026 (VND)		01 Jan 2026 (VND)	
		Carrying Amount	Allowance Value	Carrying Amount	Allowance Value
a.	**Short-term**	**33,378,729,022**	-	**45,142,935,141**	-
	Advances	4,500,000,000	-	-	-
	Phu Tho Obstetrics and Pediatrics Hospital (*)	26,000,000,000	-	43,500,000,000	-
	Collaterals and deposits	2,816,489,805	-	1,642,935,141	-
	Other receivables	62,239,217	-	-	-
b.	**Long-term**	**114,227,000,000**	-	**125,727,000,000**	-
	Phu Tho Obstetrics and Pediatrics Hospital (*)	114,227,000,000	-	125,727,000,000	-
	Total	**147,605,729,022**	-	**170,869,935,141**	-

(*) According to Contract No. 01/2025/HDCN/SARA-VIETMY dated 15 February 2025, the Company acquired the capital contribution of Sara Vietnam Joint Stock Company in Phu Tho Provincial General Hospital to invest in the construction of the Obstetrics and Pediatrics Center under Phu Tho Provincial General Hospital (currently Phu Tho Provincial Obstetrics and Pediatrics Hospital) valued at VND 204,227,000,000 for a transfer price of VND 204,227,000,000.

However, pursuant to Resolution of the Board of Directors No. 1604/NQ-HDQT dated 16 April 2025, the Company decided to withdraw capital prematurely from Phu Tho Obstetrics and Pediatrics Hospital. On 21 April 2025, the Company and Phu Tho Obstetrics and Pediatrics Hospital executed Contract Addendum No. 05 regarding premature capital withdrawal. Accordingly, the Hospital will refund the contributed amount to the Company following a schedule from 2025 to 2028.

5.6. Bad debts

	30 Jun 2026 (VND)		01 Jan 2026 (VND)	
	Cost	Recoverable Amount	Cost	Recoverable Amount
Total value of receivables and loans past due or overdue but unlikely to be recovered				
Over 03 years	259,325,128	-	259,325,128	-
National Lung Hospital	*171,239,842*	-	*171,239,842*	-
Hau Giang Tuberculosis and Lung Disease Hospital	*35,168,802*	-	*35,168,802*	-
Gia Rai Town Medical Center	*27,496,482*	-	*27,496,482*	-
Phu Tho Provincial General Hospital	*25,420,002*	-	*25,420,002*	-
Total	**259,325,128**	-	**259,325,128**	-

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

5.7. Inventories

	30 Jun 2026 (VND)		01 Jan 2026 (VND)	
	Cost	Allowance Value	Cost	Allowance Value
Merchandise	36,983,739,869	-	16,284,033,892	-
Total	**36,983,739,869**	**-**	**16,284,033,892**	**-**

5.8. Construction in progress

	30 Jun 2026 (VND)		01 Jan 2026 (VND)	
	Cost	Recoverable Amount	Cost	Recoverable Amount
Purchases	13,848,339,735	13,848,339,735	20,691,865,470	20,691,865,470
- PACS system hardware devices	*820,362,562*	*820,362,562*	*1,164,438,553*	*1,164,438,553*
- PACS system software	*13,027,977,173*	*13,027,977,173*	*18,927,438,275*	*18,927,438,275*
Total	**13,848,339,735**	**13,848,339,735**	**20,691,865,470**	**20,691,865,470**

5.9. Increase/ Decrease in tangible fixed assets

	Machinery and equipment VND	Total VND
HISTORICAL COST		
Beginning balance	54,860,290,809	54,860,290,809
- Purchases during the periods	300,500,000	300,500,000
- Disposals or transfer	-	-
Closing balance	**55,160,790,809**	**55,160,790,809**
DEPRECIATION		
Opening balance	27,772,379,962	27,772,379,962
- Charge for the period	2,535,167,838	2,535,167,838
- Disposals or transfer	-	-
Closing balance	**30,307,547,800**	**30,307,547,800**
NET BOOK VALUE		
At the beginning of the period	**27,087,910,847**	**27,087,910,847**
At the end of the period	**24,853,243,009**	**24,853,243,009**

- Net book value of tangiles fixed assets used to pledge, mortgage: VND 24,853,243,009.

- Historical cost of tangible fixed assets fully depreciated but still in use at period-end: VND 8,670,071,862.

- Tangible fixed assets awaiting disposal at period-end: None

- Details of tangible fixed assets currently held representing 10% or more of the total value of tangible fixed assets:

Asset	Historical Cost	Status
The machinery system at AMV - Parent Company	38,916,611,293	In use

5.10. Increase/ Decrease in intangible fixed assets

	Software VND	Total VND
HISTORICAL COST		
Beginning balance	59,564,895,987	59,564,895,987
- Purchases during the periods	6,500,025,735	6,500,025,735
Closing balance	**66,064,921,722**	**66,064,921,722**
AMORTIZATION		
Opening balance	26,754,536,389	26,754,536,389
- Charge for the period	3,280,645,211	3,280,645,211
- Impairment charge	-	-
Closing balance	**30,035,181,600**	**30,035,181,600**
NET BOOK VALUE		
At the beginning of the period	**32,810,359,598**	**32,810,359,598**
At the closing of the period	**36,029,740,122**	**36,029,740,122**

- Net book value of intangible fixed assets used to pledge, mortgage to secure loans at period-end: None

- Intangible fixed assets fully amortized but still in use: None

- Details of intangible fixed assets currently held representing 10% or more of the total value of intangible fixed assets:

Asset	Historical Cost	Status
PACS system - Software installed at Nghe An Lung Hospital	8,997,271,048	In use

5.11. Prepaid expenses

		30 Jun 2026 (VND)	01 Jan 2026 (VND)
a.	**Short-term**	**121,888,124**	**90,482,526**
	Tools and suppliers	70,471,456	55,482,529
	Software expenses	26,666,668	-
	Others	24,750,000	34,999,997
b.	**Long-term**	**18,168,750**	**25,436,250**
	Software expenses	18,168,750	25,436,250
	Total	**140,056,874**	**115,918,776**

5.12. Borrowings and finance lease liabilities

		01 Jan 2026 (VND)	Increase during the period (VND)	Decrase during the period (VND)	30 Jun 2026 (VND)
a.	**Short-term borrowings**	-	**133,500,000,000**	-	**133,500,000,000**
(1)	Capella Group JSC	-	133,500,000,000	-	133,500,000,000
b.	**Long-term borrowings**	**23,126,095,827**	**4,000,000,000**	-	**27,126,095,827**
(2)	Viet Capital Commercial Joint Stock Bank - Hanoi Branch	23,126,095,827	-	-	23,126,095,827
(3)	Mr. Vu Tien Dung	-	2,000,000,000	-	2,000,000,000
(4)	Ms. Nguyen Van Anh	-	2,000,000,000	-	2,000,000,000
	Total	**23,126,095,827**	**137,500,000,000**	-	**160,626,095,827**

		30 Jun 2026 (VND)	01 Jan 2026 (VND)
c.	**Current portion of long-term loans principal at the reporting date**	**23,126,095,827**	**23,126,095,827**
	Viet Capital Commercial Joint Stock Bank - Hanoi Branch	23,126,095,827	23,126,095,827
d.	**Balance as at the reporting date**	**160,626,095,827**	**23,126,095,827**
d.1	Short-term borrowings and lease liabilities (d.1 = a + c)	156,626,095,827	23,126,095,827
d.2	Long-term borrowings and lease liabilities (d.2 = b - c)	4,000,000,000	-

e. **Details of loan agreements as at 30 June 2026:**

(1) Loan from Capella Group JSC under Loan Agreement No 31.12/NV/HDVV-CPG dated 31 December 2025:

- Loan amount: 133,500,000,000 VND.
- Loan term: From the date of receipt of the first loan disbursement to 30 September 2026.
- Loan purpose: To supplement working capital of the Company.
- Interest rate: 13%/year.
- The loan is secured by the Company's right to early capital withdrawal relating to the capital contribution at Phu Tho Obstetrics and Pediatrics Hospital and all legally owned assets of the Company, including cash and cash equivalents, machinery, factories, equipment, land use rights and assets attached to land, investments, capital contributions, shares, and receivables.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

5.12. Borrowings and finance lease liabilities (Continued)

(2) Loan from Viet Capital Commercial Joint Stock Bank - Hanoi Branch under Specific Credit Agreement No. 0041900059900 dated 28 November 2019.

- Loan amount: 40,000,000,000 VND.
- Loan purpose: To purchase machinery and medical equipment serving business activities.
- Loan term: 48 month from the disbursement date of 28 November 2019; maturity date is 28 November 2023; grace period for principal repayment is 06 months.
- Initial lending interest rate: 11.5%/year. From the 13th month, the interest rate is adjusted by the Bank equal to the Bank's base rate at the adjustment serving business activities.
- The loan is secured by machinery and medical equipment formed from the loan under Mortgage Agreement on Movable Assets No. 0041900060000 dated 28 November 2019. As at 30 June 2026, the net book value of the pledged assets is VND 19,793,072,189 VND.

At the date of report issuance, this debt is past due for repayment. The requested extension period according to Official Letter No. 05/2024/CV-AMV of the Company is October 2024, which was approved by Viet Capital Commercial Joint Stock Bank under Official Letter No. 212/2024/BVbanWCV-QL&THN dated 09 April 2024. However, as of the present date, the Company has not fully repaid the aforementioned principal balance, and the Company is continuing to work with the Bank to request a debt extension.

(3) Loan from Mr. Vu Tien Dung under Business Loan Agreement No. 259/2025/HDVV dated 25 September 2025.

- Loan amount: VND 2,000,000,000.
- Loan term: 60 months.
- Loan purpose: Additional working capital for the Company.
- Interest rate: Fixed at 20%/year.

(4) Loan from Ms. Nguyen Van Anh under Business Loan Agreement No. 217/2025/HDVV dated 21 July 2025.

- Loan amount: VND 2,000,000,000.
- Loan term: 36 months.
- Loan purpose: Additional working capital for the Company.
- Interest rate: Fixed at 20%/year.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

5.13. Trade payables

		30 Jun 2026 (VND)	01 Jan 2026 (VND)
a.	**Short-term trade payables**	**22,257,001,116**	**917,335,164**
	Golab Ha Tinh Testing Center JSC	2,940,000,000	-
	AIKO International Group JSC	18,375,000,000	-
	Huong Duong Technical Science Co., Ltd	373,248,700	356,213,750
	JWB Co., Ltd	298,643,120	298,643,120
	Trade payables to other suppliers	270,109,296	262,478,294

b. **Trade payables to related parties are detailed in Note 8.3.**

5.14. Taxes and amounts due from/to the State

		01 Jan 2026 (VND)	Payable during the period	Paid during the period	30 Jun 2026 (VND)
a.	**Short-term taxes payable**				
	Value-added tax	-	22,241,882	22,241,882	-
	Import Duty	-	12,400,302	12,400,302	-
	Personal income tax	29,144,742	35,627,292	48,788,408	15,983,626
	Total	**29,144,742**	**70,269,476**	**83,430,592**	**15,983,626**
b.	**Taxes receivables**				
	Charges, fee, and other payables	6,163,428	6,163,428	-	-
	Total	**6,163,428**	**6,163,428**	**-**	**-**

The Company's tax finalization is subject to examination by tax authorities. Because tax laws and regulations applied to different transactions can be interpreted in various ways, the tax amounts presented in the Interim Separate Financial Statements may be subject to change upon final decision of the tax authorities.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

5.15. Dividends and Profits Payable

	30 Jun 2026 (VND)	01 Jan 2026 (Reclassified) (VND)
Dividends and profits payable	75,924,090,000	75,924,090,000

(*) 2019 dividends payable to shareholders according to the finalized shareholder list as at 12 January 2021. Resolution of the Board of Directors No. 1901/2026/NQ-HDQT dated 19 January 2026 regarding the change in payment schedule of 2019 dividends. Accordingly, the payment schedule is as follows: 1st tranche payment on 28 January 2027, 2nd tranche payment on 28 July 2027.

Reason for change: The Company is actively expanding production and business activities and investing in equipment and machinery for critical projects. To ensure project progress, the Company uses available capital to place orders for necessary equipment.

5.16. Accrued Expenses

		30 Jun 2026 (VND)	01 Jan 2026 (VND)
a.	**Short-term**	**34,886,183,344**	**23,968,555,935**
	Accrued loan interest	34,886,183,344	23,968,555,935

5.17. Other payables

	30 Jun 2026 (VND)	01 Jan 2026 (VND)
Short-term	**86,866,900**	**41,464,400**
Social Insurance, Health Insurance, Unemployment Insurance, Occupational Accident and Disease Insurance	79,686,900	33,984,000
Other payables	7,180,000	7,480,400

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

5.18. Owmer's equity

Reconciliation of changes in equity

	Owner's Contributed Capital (VND)	Share Premium (VND)	Retained earnings (VND)	Total (VND)
Prior year opening balance	**1,311,056,500,000**	**(395,300,000)**	**234,243,514,791**	**1,544,904,714,791**
Loss for the prior year	-	-	(42,910,980,816)	(42,910,980,816)
Current period opening balance	**1,311,056,500,000**	**(395,300,000)**	**191,332,533,975**	**1,501,993,733,975**
Loss for the current year	-	-	(42,226,243,475)	(42,226,243,475)
Current period closing balance	**1,311,056,500,000**	**(395,300,000)**	**149,106,290,500**	**1,459,767,490,500**

Capital Transactions with Owners and Distribution of Dividends/Profits

	From 01 Jan 2026 to 30 Jun 2026 (VND)	From 01 Jan 2025 to 30 Jun 2025 (VND)
Owners' contributed capital		
Opening balance	1,311,056,500,000	1,311,056,500,000
Capital contributions during the period	-	-
Capital reductions during the period	-	-
Closing balance	1,311,056,500,000	1,311,056,500,000
Dividends and profits distributed	-	-

Shares

	30 Jun 2026 (VND)	01 Jan 2026 (VND)
Number of shares authorized for issuance	**131,105,650**	**131,105,650**
Number of shares issued	**131,105,650**	**131,105,650**
Ordinary shares	131,105,650	131,105,650
Preference shares	-	-
Number of shares outstanding	**131,105,650**	**131,105,650**
Ordinary shares	131,105,650	131,105,650
Preference shares	-	-

Par value per outstanding share: 10,000 VND/share

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

6. ADDITIONAL INFORMATION FOR ITEMS PRESENTED IN THE INTERIM SEPARATE INCOME STATEMENT

6.1. Revenue from Sales of Goods and Rendering of Services

	From 01 Jan 2026 to 30 Jun 2026 (VND)	From 01 Jan 2025 to 30 Jun 2025 (VND)
Revenue from sales goods and rendering of services	11,132,161,822	6,427,336,856
Total	**11,132,161,822**	**6,427,336,856**

6.2. Revenue deductions

	From 01 Jan 2026 to 30 Jun 2026 (VND)	From 01 Jan 2025 to 30 Jun 2025 (VND)
Sales returns	19,186,667	-
Total	**19,186,667**	**-**

6.3. Cost of goods sold

	From 01 Jan 2026 to 30 Jun 2026 (VND)	From 01 Jan 2025 to 30 Jun 2025 (VND)
Cost of goods and services rendered	10,552,887,816	7,366,727,194
Total	**10,552,887,816**	**7,366,727,194**

6.4. Financial income

	From 01 Jan 2026 to 30 Jun 2026 (VND)	From 01 Jan 2025 to 30 Jun 2025 (VND)
Interest on deposits and loans	236,324	364,401
Dividends are distributed profits	-	17,009,339,331
Total	**236,324**	**17,009,703,732**

6.5. Financial expense

	From 01 Jan 2026 to 30 Jun 2026 (VND)	From 01 Jan 2025 to 30 Jun 2025 (VND)
Interest expense	11,199,764,397	2,293,791,366
Provision for investment impairment	28,382,853,790	20,442,100,197
Total	**39,582,618,187**	**22,735,891,563**

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

6.6. Other income

	From 01 Jan 2026 to 30 Jun 2026 (VND)	From 01 Jan 2025 to 30 Jun 2025 (VND)
Gains from disposals and derecognitions of fixed assets	-	140,000,000
Other income	601	217,607
Total	**601**	**140,217,607**

6.7. Other expenses

	From 01 Jan 2026 to 30 Jun 2026 (VND)	From 01 Jan 2025 to 30 Jun 2025 (VND)
Penalties for late tax and insurance payments	6,522,681	42,395,941
Other expenses	2,087,390	-
Total	**8,610,071**	**42,395,941**

6.8. Selling expenses and General and administrative expenses

		From 01 Jan 2026 to 30 Jun 2026 (VND)	From 01 Jan 2025 to 30 Jun 2025 (VND)
a.	**General and administrative expenses**	**3,195,339,481**	**3,691,974,670**
	Administrative staff cost	2,211,065,227	2,793,470,685
	Depreciation of fixed assets	2,996,214	2,996,214
	Outsources service expenses	953,446,037	874,939,576
	Other cash expenses	27,832,003	20,568,195
b.	**Selling expenses**	-	**135,413,326**
	Staff cost	-	133,333,326
	Outsources service expenses	-	2,080,000
	Total	**3,195,339,481**	**3,827,387,996**

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

6.9. Corporate income tax expense

	From 01 Jan 2026 to 30 Jun 2026 (VND)	From 01 Jan 2025 to 30 Jun 2025 (VND)
Accounting profit before tax	(42,226,243,475)	(10,395,144,499)
Tax calculated at the applicable corporate income tax rate	-	-
Adjustments		
- Depreciation expenses of fixed assets not service of production and business	389,166,113	389,166,113
- Penalties for late tax and insurance payments	1,304,536	8,479,188
- Other non-deductible expenses	417,478	-
- Dividends and distributed profits	-	(3,401,867,866)
Corporate income tax expense (*)	-	-
Current corporate income tax expense	-	-
Deferred corporate income tax expense	-	-

(*) Estimated Corporate Income Tax expense for the accounting period is based on taxable income and is subject to adjustments upon tax audit.

6.10. Operating expenses by elements

	From 01 Jan 2026 to 30 Jun 2026 (VND)	From 01 Jan 2025 to 30 Jun 2025 (VND)
Raw materials and consumables	-	48,282,000
Labor costs	2,226,128,999	2,926,804,011
Depreciation and amortisation	5,815,813,049	5,277,338,239
Outsourced services	818,773,709	934,519,576
Other cash expenses	263,131,706	7,286,196
Total	**9,123,847,463**	**9,194,230,022**

7. ADDITIONAL INFORMATION TO ITEMS IN THE INTERIM SEPARATE CASH FLOW STATEMENT

7.1 Proceeds from Borrowings

	From 01 Jan 2026 to 30 Jun 2026 (VND)
Proceeds from borrowings under loan agreements	137,500,000,000
Proceeds from other borrowings	-

8. Other information

8.1. Financial instruments

The Company is exposed to the following risks arising from the use of financial instruments: market risk, credit risk and liquidity risk.

Management has overall responsibility for establishing and overseeing the Company's financial risk management framework. The Board of Management establishes policies to identify and analyse the risks faced by the Company, sets appropriate risk limits and controls, and monitors risks and compliance with risk limits. The risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities.

The Board of Management has reviewed and approved the following risk management policies:

(i) Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises four types of risk: interest rate risk, currency risk, commodity price risk and other price risk.

Interest rate Rrsk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to interest rate risk mainly relates to cash, short-term deposits and borrowings.

The Company manages interest rate risk by analysing market conditions in order to obtain favourable borrowing rates while maintaining its exposure within acceptable risk limits.

Foreign Currency Risk

Foreign currency risk is the risk that the fair value or future cash flows of financial instruments will fluctuate because of changes in foreign exchange rates. The Company is exposed to exchange rate risk arising directly from its operating activities.

The Company is exposed to foreign currency risk through purchase and sale transactions denominated in currencies other than the Company's accounting currency.

(ii) Credit Risk

Credit risk is the risk that one party to a financial instrument or contractual arrangement will fail to perform its obligations, resulting in a financial loss to the other party. The Company is exposed to credit risk from its operating activities (primarily trade receivables) and from its financing activities, including bank deposits, loans and other financial instruments.

Trade Receivables

The Company regularly monitors outstanding trade receivables. For significant customers, the Company assesses any deterioration in credit quality at the reporting date. The Company seeks to maintain strict control over outstanding receivables and has established credit control procedures to minimise credit risk. As the Company's trade receivables relate to a large number of customers, credit risk is not significantly concentrated with any individual customer.

The Company establishes impairment provisions to reflect estimated losses on trade receivables, other receivables and investments. These provisions mainly comprise specific losses relating to individually impaired customers.

Bank Deposits

The Company mainly maintains deposits with reputable banks in Vietnam. Credit risk relating to bank deposits is managed by the Company's treasury department in accordance with approved policies. The maximum credit exposure relating to these balance sheet items at the reporting date equals their carrying amounts as disclosed in Note 5.1. The Company considers the concentration of credit risk relating to bank deposits to be low

(iii) Liquibity Risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting financial obligations due to a shortage of funds. The Company's liquidity risk mainly arises from mismatches in the maturities of financial assets and financial liabilities.

The Company manages liquidity risk by maintaining sufficient cash, cash equivalents and available bank borrowings to meet its operating requirements and minimise the effects of fluctuations in cash flows.

The following table analyses the Company's non-derivative financial assets and financial liabilities into relevant maturity groupings based on the remaining period from the reporting date to the contractual maturity date. The amounts presented represent undiscounted contractual cash flows. The disclosure of non-derivative financial assets is necessary to understand the Company's liquidity risk management, as liquidity is managed on a net asset and liability basis.

	Under 1 year	From 1 to 5 years	Total
As at 30 June 2026			
Carrying amount:			
Cash and cash equivalents	1,210,948,406	-	1,210,948,406
Trade receivables	23,389,694,937	-	23,389,694,937
Other receivables	28,878,729,022	114,227,000,000	143,105,729,022
Other financial assets	-	-	-
Less:			
Allowance for doubtful debts	(259,325,128)	-	(259,325,128)
Total financial assets	**53,220,047,237**	**114,227,000,000**	**167,447,047,237**
Borrowings	156,626,095,827	4,000,000,000	160,626,095,827
Trade payables	22,257,001,116	-	22,257,001,116
Other payables and accrued expenses	110,897,140,244	-	110,897,140,244
Total financial liabilities	**289,780,237,187**	**4,000,000,000**	**293,780,237,187**
Net liquidity gap	**(236,560,189,950)**	**110,227,000,000**	**(126,333,189,950)**

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

	Under 1 year	From 1 to 5 years	Total
As at 1 January 2026			
Carrying amount:			
Cash and cash equivalents	1,972,095,736	-	1,972,095,736
Trade receivables	18,793,097,280	-	18,793,097,280
Other receivables	45,142,935,141	125,727,000,000	170,869,935,141
Other financial assets	-	-	-
Less:			
Allowance for doubtful debts	(259,325,128)	-	(259,325,128)
Total financial assets	**65,648,803,029**	**125,727,000,000**	**191,375,803,029**
Borrowings	23,126,095,827	-	23,126,095,827
Trade payables	917,335,164	-	917,335,164
Other payables and accrued expenses	99,934,110,335	-	99,934,110,335
Total financial liabilities	**123,977,541,326**	**-**	**123,977,541,326**
Net liquidity gap	**(58,328,738,297)**	**125,727,000,000**	**67,398,261,703**

The Company considers the concentration of debt repayment risk to be low and believes that it has adequate access to the necessary funding sources.

(iv) Fair value

The carrying amounts, net of allowance, of short-term receivables, bank deposits, trade payables and other payables approximate their respective fair values.

	Carrying amount		Fair value	
	30 Jun 2026	**01 Jan 2026**	**30 Jun 2026**	**01 Jan 2026**
Financial Assets				
Held-to-maturity investments	-	-	-	-
Loans and receivables	166,495,423,959	189,663,032,421	166,236,098,831	189,403,707,293
Trade receivables	*23,389,694,937*	*18,793,097,280*	*23,130,369,809*	*18,533,772,152*
Other receivables	*143,105,729,022*	*170,869,935,141*	*143,105,729,022*	*170,869,935,141*
Available-for-sale financial assets	1,210,948,406	1,972,095,736	1,210,948,406	1,972,095,736
Long-term investments	-	-	-	-
Cash and cash equivalents	*1,210,948,406*	*1,972,095,736*	*1,210,948,406*	*1,972,095,736*
Total	**167,706,372,365**	**191,635,128,157**	**167,447,047,237**	**191,375,803,029**
Financial Liabilities				
Financial Liabilities	293,780,237,187	123,977,541,326	293,780,237,187	123,977,541,326
Borrowings	*160,626,095,827*	*23,126,095,827*	*160,626,095,827*	*23,126,095,827*
Trade payables	*22,257,001,116*	*917,335,164*	*22,257,001,116*	*917,335,164*
Other payables	*110,897,140,244*	*99,934,110,335*	*110,897,140,244*	*99,934,110,335*
Total	**293,780,237,187**	**123,977,541,326**	**293,780,237,187**	**123,977,541,326**

The fair values of the Company's financial assets and financial liabilities were not formally determined as at 30 June 2026 and 01 January 2026. However, the Board of Management believes that the carrying amounts of these financial assets and financial liabilities approximate their fair values at the reporting dates and that any differences are not material.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

8.2. Events after the End of the Accounting Period

As at the date of this report, the Board of Management believes that there have been no events occurring after the end of the accounting period that would materially affect or require adjustment to the amounts and disclosures presented in the Company's interim financial statements.

8.3. Related Party Information

Related parties of the Company include: key management personnel, individuals related to key management personnel, and other related parties.

List of other related parties with the Company during the accounting period and as at the end of the accounting period:

Related party	Relationship
Viet My Hospital Investment JSC	Subsidiary
Ha Long Kyoto Technology Development JSC	Subsidiary
Golab Uong Bi Testing Center JSC	Subsidiary
Song Hau New Technology Research and Application JSC	Subsidiary
Ha Dong Clinic JSC	Subsidiary
Hoa Binh Clinic JSC	Subsidiary
Viet Tri Clinic JSC	Subsidiary
Gia Lam High-Tech Clinic JSC	Subsidiary
Medicare Can Tho Clinic JSC	Subsidiary
Medicare Hau Giang Clinic JSC	Subsidiary
Medicare Soc Trang Clinic JSC	Subsidiary
Golab Nga Bay Testing Center JSC	Subsidiary
Leopard Solutions JSC	Subsidiary
Famicare Thu Duc JSC	Indirect subsidiary
Associates as disclosed in Note 5.2	Associate
Associates with capital contribution from subsidiaries	Associate

As at June 30, 2026, balances with related parties are as follows:

Related party	30 Jun 2026 (VND)	01 Jan 2026 (VND)
Short-term trade receivables	**12,779,187,482**	**11,689,578,182**
Leopard Solutions JSC	70,000,000	-
Viet Tri Clinic JSC	-	180,390,700
Nghe An Clinic JSC	110,416,851	110,416,851
Golab Binh Dinh Testing Center JSC	1,120,000,000	1,120,000,000
Golab Da Nang Testing Center JSC	1,120,000,000	1,120,000,000
Golab Ha Tinh Testing Center JSC	1,149,807,175	1,149,807,175
Golab Hai Duong Testing Center JSC	1,120,000,000	1,120,000,000

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

Related party	30 Jun 2026 (VND)	01 Jan 2026 (VND)
Golab Hai Phong Testing Center JSC	1,120,000,000	1,120,000,000
Golab Ninh Binh Testing Center JSC	36,172,300	36,172,300
Golab Quang Binh Testing Center JSC	1,120,000,000	1,120,000,000
Golab District 5 Testing Center JSC	1,120,000,000	1,120,000,000
Golab Thai Binh Testing Center JSC	1,120,000,000	1,120,000,000
Golab Thai Nguyen Testing Center JSC	1,200,000,000	-
Golab Thanh Hoa Testing Center JSC	1,120,000,000	1,120,000,000
Golab Vinh Yen Testing Center JSC	1,252,791,156	1,252,791,156
Short-term trade payables	**2,940,000,000**	**-**
Golab Ha Tinh Testing Center JSC	2,940,000,000	-

During the accounting period from 01 January 2026 to 30 June 2026, major transactions with related parties were as follows:

Related party	From 01 Jan 2026 to 30 Jun 2026 (VND)	From 01 Jan 2025 to 30 Jun 2025 (VND)
Purchases of goods and services	**2,800,000,000**	**4,030,000,000**
Golab Ha Tinh Testing Center JSC	2,800,000,000	-
Medicare Hau Giang Clinic JSC	-	4,030,000,000
Sales of goods and rendering of services	**250,000,000**	**416,409,384**
Leopard Solutions JSC	250,000,000	-
Viet Tri Clinic JSC	-	171,800,668
Nghe An Clinic JSC	-	140,158,906
Golab Phap Van Testing Center JSC	-	35,000,000
Golab Ninh Binh Testing Center JSC	-	69,449,810

Salary, remuneration, bonus, and other benefits of key management personnel:

Full name	Position	From 01 Jan 2026 to 30 Jun 2026 (VND)	From 01 Jan 2025 to 30 Jun 2025 (VND)
Mrs. Dang Thi Nuong	Director	121,000,000	121,000,000
Total		**121,000,000**	**121,000,000**

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (Continued)

For the accounting period from 01 January 2026 to 30 June 2026

8.4. Segment reporting

During the accounting period from 01 January 2026 to 30 June 2026, the Company's business activities primarily consisted of trading medical equipment and medical testing reagents; therefore, the Company does not present primary segment reporting.

Geographical segment reporting (secondary report): Geographical segment reporting is based on the location of customers generating revenue for the segment. During the accounting period from 01 January 2026 to 30 June 2026, the Company's business activities were mainly generated domestically, so the Company does not prepare secondary segment reporting (by geographical area).

8.5. Comparative information

Comparative figures on the interim separate statement of financial position and related notes are taken from the financial statements for the fiscal year ended 31 December 2025 of American Vietnamese Biotech INC, which were audited by International Assessment and Auditing Company Limited.

Comparative figures on the interim separate statement of income, interim separate cash flow statement, and related notes are taken from the interim separate financial statements for the accounting period from 01 January 2025 to 30 June 2025 of American Vietnamese Biotech INC, which were reviewed by Nhan Tam Viet Auditing Company Limited.

As disclosed in Note 3.2, starting from 01 January 2026, the Company applies Circular No. 99/2025/TT-BTC retrospectively. Certain comparative figures have been reclassified to conform with the provisions of Circular No. 99/2025/TT-BTC relating to the presentation of interim separate financial statements. The comparison table of figures presented in the prior period before and after reclassification is as follows:

Interim Statement of Financial Position

Item	Circular No. 99		Circular No. 200	
	Code	01 Jan 2026 (VND) (Reclassified)	Code	31 Dec 2025 (VND) (Audied F/S)
Dividends and profits payable	313	75,924,090,000		
Other short-term payables	320	41,464,400	319	75,965,554,400

Ho Chi Minh, 28 August 2026

PREPARER	CHIEF ACCOUNTANT	DIRECTOR
TRAN HANG NGA	NGUYEN THU HUYEN	DANG THI NUONG

M.S.D.N: 3800237998 - C.T.C.P CÔNG TY CỔ PHẦN SẢN XUẤT KINH DOANH DƯỢC VÀ TRANG THIẾT BỊ Y TẾ VIỆT MỸ VIỆT NAM